Investigation of the effect of Interleukin-1 receptor antagonist (IL-Ira) on markers of inflammation in non-ST elevation acute coronary syndromes (The MRC-ILA-HEART Study)

作     者：Crossman, David C. Morton, Allison C. Gunn, Julian P. Greenwood, John P. Hall, Alistair S. Fox, Keith Aa Lucking, Andrew J. Flather, Marcus D. Lees, Belinda Foley, Claire E. 

作者机构：Univ Sheffield Sch Med & Biomed Sci Cardiovasc Res Unit Sheffield S10 2RX S Yorkshire England Leeds Gen Infirm Acad Unit Cardiovasc Med Leeds LS1 3EX W Yorkshire England Univ Edinburgh Queens Med Res Inst Ctr Cardiovasc Sci Edinburgh EH16 4TJ Midlothian Scotland Royal Brompton & Harefield NHS Trust Clin Trials Evalut Unit London SW3 6NP England 

出 版 物：《TRIALS》 (心血管内科的电流控制试验)

年 卷 期：2008年第9卷第2008期

页      面：8-8页

核心收录：

学科分类：1002[医学-临床医学] 1001[医学-基础医学(可授医学、理学学位)] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学] 

基　　金：Medical Research Council [G0502131] Funding Source: Medline MRC [G0502131] Funding Source: UKRI 

主　　题：Acute Coronary Syndrome Cardiac Magnetic Resonance Acute Coronary Syndrome Patient Data Monitoring Committee Trial Steering Committee 

摘      要：Background: Acute Coronary Syndromes account for 15% of deaths in the UK, and patients remain at significant risk of re-admission for future complications and death. Pathologically the underlying process of atherosclerosis is driven by inflammatory mechanisms, which are activated in ACS patients. Previous studies have investigated the role of inflammatory markers in this process, including interleukin 1 (IL-1) and C Reactive Protein (CRP). Pre-clinical studies indicate that IL-1 may be a primary driver of ACS and that the naturally occurring interleukin-I receptor antagonist (IL-Ira) may inhibit the atherosclerotic process. This study will investigate the effects of IL-Ira on inflammatory markers in man. Methods/design: Three centres in the UK are planning to recruit 186 Non-ST elevation myocardial infarction patients to receive either interleukin-I receptor antagonist (Anakinra) or matching placebo. Patients will receive a daily subcutaneous injection of either study drug or placebo over a 14 day period. The primary outcome is area under the curve of high sensitivity C-Reactive Protein (CRP) over the first 7 days. Discussion: The MRC-ILA-HEART Study is a proof of concept clinical trial investigating the effects of IL-Ira upon markers of inflammation in patients with Non-ST elevation myocardial infarction. It is hoped this will provide new and exciting information in relation to an anti-inflammatory strategy for patients with acute coronary syndrome. Trial registration: ISRCTN89369318.